Rubedo Life Sciences
Rubedo Life Sciences is a Senolytics & Cellular Health company founded in 2018 and based in Sunnyvale, United States. It has raised $52M in total funding, most recently a Series A in 2024.
Founded in 2018 in Sunnyvale, California by Marco Quarta, Mark Gallop and Julian Klein, Rubedo Life Sciences develops selective cellular-rejuvenation medicines that target senescent cells linked to chronic age-related diseases. Its ALEMBIC drug-discovery platform profiles senescent-cell subpopulations to identify targets and design selective small molecules. The lead candidate RLS-1496, described as a first-in-class topical GPX4 modulator targeting pathologic senescent cells, entered a Phase 1 trial; the company also won FDA IND clearance for RLS-1496 in actinic keratosis. Rubedo closed a $40M Series A in April 2024 led by Khosla Ventures and Ahren Innovation Capital, for roughly $52M raised. Frederick C. Beddingfield III serves as CEO.
RLS-1496 is positioned as the first GPX4 modulator targeting senescent cells to reach a human trial, a key test of the senolytics thesis.
rubedolife.com ↗·Senolytics & Cellular Health·
United States·private 
